0001415889-23-015986.txt : 20231207
0001415889-23-015986.hdr.sgml : 20231207
20231207180010
ACCESSION NUMBER: 0001415889-23-015986
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231206
FILED AS OF DATE: 20231207
DATE AS OF CHANGE: 20231207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dake Benjamin T
CENTRAL INDEX KEY: 0001869248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 231473524
MAIL ADDRESS:
STREET 1: C/O AEROVATE THERAPEUTICS, INC.
STREET 2: 200 BERKELEY STREET, FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-12072023_061201.xml
X0508
4
2023-12-06
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001869248
Dake Benjamin T
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
SEE REMARKS
1
Common Stock
2023-12-06
4
M
0
2411
1.74
A
3702
D
Common Stock
2023-12-06
4
M
0
7872
2.14
A
11574
D
Common Stock
2023-12-06
4
S
0
10283
16.1070
D
1291
D
Stock Option (Right to Buy)
1.74
2023-12-06
4
M
0
905
0
D
2030-09-03
Common Stock
905
906
D
Stock Option (Right to Buy)
1.74
2023-12-06
4
M
0
1506
0
D
2030-09-03
Common Stock
1506
12055
D
Stock Option (Right to Buy)
2.14
2023-12-06
4
M
0
1019
0
D
2031-04-01
Common Stock
1019
16294
D
Stock Option (Right to Buy)
2.14
2023-12-06
4
M
0
6853
0
D
2031-04-01
Common Stock
6853
123346
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.455, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.
A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.
Officer Title: President, Chief Operating Officer and Secretary
/s/ George A. Eldridge, Attorney-in-Fact
2023-12-07